Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non- neutropenic models of invasive candidiasis  N.P. Wiederhold, L.K.

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

L.H. Su, T.L. Wu, C.H. Chiu  Clinical Microbiology and Infection 
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model  G.L. Daikos, A. Panagiotakopoulou,
Detection of fungal DNA in lysis–centrifugation blood culture for the diagnosis of invasive candidiasis in neonatal patients  L. Trovato, P. Betta, M.G.
J. Gonçalves-Pereira, A. Martins, P. Póvoa 
Gut bacterial microbiota and obesity
L.H. Su, T.L. Wu, C.H. Chiu  Clinical Microbiology and Infection 
T. Schneider, J. Halter, D. Heim, J. Passweg, M. Stern, A. Tichelli, M
W.W. Hope, G.L. Drusano  Clinical Microbiology and Infection 
Anidulafungin for the treatment of invasive candidiasis
D. Khalil, M. Hultin, M.U. Rashid, B. Lund 
Clinical Microbiology and Infection
Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection 
Herpes zoster in non-hospitalized children
Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era  T.I. Pedersen, M. Howitz, C. Østergaard  Clinical.
E. Bronska, J. Kalmusova, O. Dzupova, V. Maresova, P. Kriz, J. Benes 
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Candida glabrata fungaemia in intensive care units
Louis Pasteur, from crystals of life to vaccination
Potential risk factors for infection with Candida spp
Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.  H. Wisplinghoff, H. Seifert,
Clinical Microbiology and Infection
Clinical Microbiology and Infection
J. Gonçalves-Pereira, A. Martins, P. Póvoa 
Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice  Nacer Lounis, Baohong Ji, Chantal Truffat-Pernot,
Results from a mathematical model for human monocytic ehrlichiosis
Vector control: a cornerstone in the malaria elimination campaign
J.P. Donnelly, B.E. De Pauw  Clinical Microbiology and Infection 
A. Solé, P. Morant, M. Salavert, J. Pemán, P. Morales 
Training for the infectious diseases speciality in Norway
Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria  Inga Odenholt, Elisabeth Löwdin,
Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit  E. Theocharidou, B. Agarwal, G. Jeffrey,
Elements of design: the knowledge on which we build
Levofloxacin in the treatment of ventilator-associated pneumonia
G. Pappas  Clinical Microbiology and Infection 
Evolving epidemiology of invasive Haemophilus infections in the post-vaccination era: results from a long-term population-based study  M.R. Berndsen,
Metagenomics and probiotics
W.A. Craig  Clinical Microbiology and Infection 
Voriconazole concentrations and outcome of invasive fungal infections
Recent developments in staphylococcal scalded skin syndrome
Continuous high-dose vancomycin combination therapy for methicillin-resistant staphylococcal prosthetic hip infection: a prospective cohort study  V.
Systematic review of antibiotic consumption in acute care hospitals
Update on antifungal resistance in Aspergillus and Candida
The importance of strain variation in virulence of Candida dubliniensis and Candida albicans: results of a blinded histopathological study of invasive.
Present status of the detection of antifungal resistance: the perspective from both sides of the ocean  M. Cuenca-Estrella, J.L. Rodríguez-Tudela  Clinical.
Eleven-year retrospective survey of candidaemia in a university hospital in southwestern Greece  A. Spiliopoulou, S. Vamvakopoulou, C. Bartzavali, G.
M. Bassetti, M.P. Molinari, M. Mussap, C. Viscoli, E. Righi 
Abstracts cont. Clinical Microbiology and Infection
Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida 
Hanneke J. van Deventer, Wil H. Goessens, Arjen J. van Vliet, Henry A
Statin use and clinical outcomes among pneumonia patients
Clinical Microbiology and Infection
Changing pattern of candidaemia 2001–2006 and use of antifungal therapy at the University Hospital of Vienna, Austria  E. Presterl, F. Daxböck, W. Graninger,
Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis  D.C. Sheppard, K.A. Marr, D.N.
Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis  J. Gavaldá, T. Martín, P.
Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice  L.K. Najvar, R. Bocanegra, N.P. Wiederhold, C.
Serum HBV pgRNA as a clinical marker for cccDNA activity
Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij 
J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin 
Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre  R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli 
Virology: a scientific discipline facing new challenges
Serum ferritin levels in West Nile encephalitis
Modelling during an emergency: the 2009 H1N1 influenza pandemic
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species†   C.B. Moore,
O. Megged, A.M. Yinnon, D. Raveh, B. Rudensky, Y. Schlesinger 
J.L. Balcázar  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Presentation transcript:

Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non- neutropenic models of invasive candidiasis  N.P. Wiederhold, L.K. Najvar, R. Bocanegra, W.R. Kirkpatrick, T.F. Patterson  Clinical Microbiology and Infection  Volume 18, Issue 2, Pages E20-E23 (February 2012) DOI: 10.1111/j.1469-0691.2011.03712.x Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Survival in neutropenic (clear symbols) and non-neutropenic (black symbols) mice infected intravenously with Candida albicans ATCC 90028. Antifungal therapy began 24 h post-inoculation. Groups consisted of untreated controls (n = 23 and 20 neutropenic and non-neutropenic mice, respectively), anidulafungin 1 mg/kg/day (circles; n = 21 mice per model) and 5 mg/kg/day (diamonds; n = 21 mice per model), or fluconazole 5 mg/kg/day (circles; n = 20 mice per model) and 10 mg/kg/day (diamonds; n = 19 mice per model). Both antifungals were administered intravenously for 7 days and mice were followed off therapy until day 21 post-inoculation. Median survival was significantly longer for both doses of anidulafungin and fluconazole compared with controls in neutropenic and non-neutropenic mice. Clinical Microbiology and Infection 2012 18, E20-E23DOI: (10.1111/j.1469-0691.2011.03712.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Changes in fungal burden within kidney tissue and serum (1 → 3)-β-D-glucan over time in neutropenic (n = 5 per group) and non-neutropenic (n = 10 per group) mice infected intravenously with C. albicans ATCC 90028. Groups consisted of untreated controls, anidulafungin 1 and 5 mg/kg/day, or fluconazole 5 and 10 mg/kg/day. Mean values and standard error of the mean are presented. For the fungal burden data, white bars depict data from the neutropenic model and grey bars the data from the non-neutropenic model. For the (1 → 3)-β-D-glucan data, clear symbols and dotted lines demonstrate data from the neutropenic model and black symbols and solid lines data from the non-neutropenic model. *p-value <0.05 vs. untreated controls. Clinical Microbiology and Infection 2012 18, E20-E23DOI: (10.1111/j.1469-0691.2011.03712.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions